De Novo device
everlinQ endoAVF System
Tva Medical, Inc. · Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access (PQK, Class II) · First FDA decision Jun 22, 2018, newest Jun 22, 2018Kidney failure and dialysisVascular access
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
3
Naming "everlinQ endoAVF"
MAUDE reports
6
Brand "everlinQ endoAVF", since 2015
PubMed studies
0
Mentioning "everlinQ endoAVF"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing everlinQ endoAVF System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- everlinQ endoAVF SystemNew device typeDe Novo
DEN160006 · Decided Jun 22, 2018 · 870 days after receipt
Device type: Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access (PQK) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Non-Invasive Peripheral Venous Vascular and Hemodialysis Access StudiesLocal determinationIn effectL35751WPS Insurance CorporationUpdated Feb 20, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "everlinQ endoAVF", any status and sponsor, newest update first.
- everlinQ endoAVF Post Market StudyTerminated
C. R. BardPublic (BDX)
NCT02682420 · 100 participants · Start Sep 20, 2016 · Primary completion Aug 2019
Device: everlinQ endoAVF System · For: Chronic Kidney Disease
Sites: Vancouver, Canada; Dresden, Germany; Düsseldorf, Germany · 11 sites in all
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "everlinQ endoAVF", and for the whole product code for context.
This brand
6 reports: 2 malfunction, 4 injury, 0 death
Whole product code PQK
492 reports: 273 malfunction, 212 injury, 7 death
Newest reports for this brand
2020394-2019-00273 · Received Apr 12, 2019 · Event dated Mar 5, 2019
Device type: Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access (PQK)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Stenosis
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "everlinQ endoAVF"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code PQK.
- Ellipsys Vascular Access System (Ellipsys System)Avenu Medical · De Novo 2019
- WavelinQ Plus EndoAVF SystemC.R. Bard, Inc. · 510(k) 2019
- WavelinQ 4F EndoAVF SystemC.R. Bard, Inc. · 510(k) 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.